Can infections trigger sarcoidosis?

Lampejo, Temi; Bhatt, Naman

doi:10.1016/j.clinimag.2022.01.006

Cited by 2 publications

(3 citation statements)

References 11 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the common observation of intense inflammatory side effects and non-specific peripheral adenopathy induced by COVID-19 vaccination in otherwise healthy individuals, more work is needed to understand how inflammatory events during COVID-19 may precipitate or accentuate sarcoidosis activity. We agree that caution is indicated in ‘attributing the development of sarcoidosis to…severe acute respiratory syndrome-CoV-2’ [35]: while the association may be causal in some cases, the overall risk of infection-induced sarcoidosis appears exceptionally low among the vast number of patients to date with a history of COVID-19, suggesting that multiple risk factors may be involved in the relatively few cases that develop.…”

Section: Infection Risk In Patients With Established Sarcoidosismentioning

confidence: 82%

“…. .severe acute respiratory syndrome-CoV-2' [35]: while the association may be causal in some cases, the overall risk of infection-induced sarcoidosis appears exceptionally low among the vast number of patients to date with a history of COVID-19, suggesting that multiple risk factors may be involved in the relatively few cases that develop.…”

Section: Coronavirus Disease 2019mentioning

confidence: 99%

See 1 more Smart Citation

Considerations and clinical management of infections in sarcoidosis

Chen

Patterson

2023

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of review To summarize data from recent reports about risks and outcomes of the infections most often reported in patients with sarcoidosis. Recent findings Rates of fungal infections and other severe infections are higher in patients with sarcoidosis compared to controls. Immunosuppression further increases the risk for an infection requiring hospitalization. In contrast, outcomes of coronavirus disease 2019 (COVID-19) are not worse unless lung impairment or other comorbidities are present. Summary Tuberculosis, fungal infections, and other severe infections requiring hospital admission are, fortunately, relatively rare in patients with sarcoidosis who live in nonendemic regions. However, ongoing vigilance is required when the course of sarcoidosis is atypical or inexplicably progressive, as costs are high when these infections are missed. In contrast, COVID-19 and other respiratory viral illnesses are common, including among patients with sarcoidosis. When organ impairment is minimal, an underlying diagnosis of sarcoidosis does not appear to increase the risk of severe COVID-19, but patients may have higher risks due to comorbidities, which are important factors to address in routine sarcoidosis care. The burden from respiratory viral events, including impacts on quality of life and life functionality including work capacity, is unknown and is important to measure.

show abstract

Section: Infection Risk In Patients With Established Sarcoidosismentioning

confidence: 82%

Section: Coronavirus Disease 2019mentioning

confidence: 99%

Considerations and clinical management of infections in sarcoidosis

Chen

Patterson

2023

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

“…Granuloma formation occurs in intrathoracic lymph nodes, lungs, skin, heart, and other organs upon contact with antigen-presenting cells (macrophages, dendritic cells, activated epithelial cells) by a triggering agent, followed by the development of unregulated autoimmune inflammation, additionally characterized by an imbalance between pro- and anti-inflammatory acquired immune cell subsets (T- and B lymphocytes) as well as regulatory T cells ( 7–9 ). Moreover, a tight link between sarcoidosis and COVID-19 caused by SARS-CoV-2 has been hypothesized, which may be another new trigger agent related to sarcoidosis, capable of either provoking or exacerbating it ( 10–12 ).…”

Section: Introductionmentioning

confidence: 99%

Sarcoidosis-related autoimmune inflammation in COVID-19 convalescent patients

Rubinstein,

Kudryavtsev,

Malkova

et al. 2023

Front. Med.

View full text Add to dashboard Cite

Currently, there are a large number of reports about the development of autoimmune conditions after COVID-19. Also, there have been cases of sarcoid-like granulomas in convalescents as a part of the post-COVID-19 syndrome. Since one of the etiological theories of sarcoidosis considers it to be an autoimmune disease, we decided to study changes in the adaptive humoral immune response in sarcoidosis and SARS-CoV-2 infection and to find out whether COVID-19 can provoke the development of sarcoidosis. This review discusses histological changes in lymphoid organs in sarcoidosis and COVID-19, changes in B cell subpopulations, T-follicular helper cells (Tfh), and T-follicular regulatory cells (Tfr), and analyzes various autoantibodies detected in these pathologies. Based on the data studied, we concluded that SARS-CoV-2 infection may cause the development of autoimmune pathologies, in particular contributing to the onset of sarcoidosis in convalescents.

show abstract

Can infections trigger sarcoidosis?

Cited by 2 publications

References 11 publications

Considerations and clinical management of infections in sarcoidosis

Considerations and clinical management of infections in sarcoidosis

Sarcoidosis-related autoimmune inflammation in COVID-19 convalescent patients

Contact Info

Product

Resources

About